Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
|Videos|December 16, 2020
Linda Fan, MD, on telehealth in the second stage of COVID-19
In this video interview, Senior Editor Angie DeRosa talks with Linda Fan, MD, about the rise of telehealth as the pandemic enters the second stage.
Advertisement
This expert interview features Linda Fan, MD, as she discusses her experience with telehealth since the beginning of the pandemic and how it's evolving.
Listen to this interview in the latest episode of Pap Talk
Read Fan's peer-reviewed article, Guide to effective virtual visits during COVID-19,
Advertisement
Related to this article
Distress, not low libido alone, defines HSDD, which requires a biopsychosocial evaluation, according to Holly N. Thomas, MD, MS.
Open-ended questions help ob-gyns untangle GSM and low desire and build adherence-focused treatment plans, according to Sheryl Kingsberg, PhD.
The investigational Evident test requires 3 tumor markers on the same extracellular vesicle to flag early-stage ovarian cancer.
Real-world fezolinetant (Veozah) sleep data help ob-gyns counsel patients hesitant about hormone therapy, according to Marla Shapiro, CM, MDCM.
Cultural upbringing gives context to sexual dysfunction but does not make the diagnosis, according to Sameena Rahman, MD, FACOG.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Before Pregnancy Begins: Why the Timing of Carrier Screening Matters
2
JoAnn V. Pinkerton, MD, MSCP, on elinzanetant across menopause subpopulations at TMS 2026
3
Brain fog at menopause: Separating normal change from dementia
4
Neurokinin receptor antagonists improve menopausal sleep disturbance
5